A study with ketoconazole and octreotide combination therapy for treatment of Cushing’s disease

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-003264-77

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The primary endopoint is to determine whether ketoconazole/octreotide combination therapy, followed by octreotide monotherapy, is an effective treatment for Cushing's disease.


Critère d'inclusion

  • Cushing's disease (which is caused by an ACTH producing pituitary adenoma)

Liens